Skip to main content
Fig. 2 | Journal of Ovarian Research

Fig. 2

From: MiR-29c-3p, a target miRNA of LINC01296, accelerates tumor malignancy: therapeutic potential of a LINC01296/miR-29c-3p axis in ovarian cancer

Fig. 2

LINC01296 directly targets miR-29c-3p. a The binding sequence showed that 3′-UTR of LINC01296 contains the binding site of miR-29c-3p; b The fluorescence intensity of WT-LINC01296 and miR-29c-3p mimic co-transfected HEK-293 T cells was significantly declined (P < 0.01), while the fluorescence intensity of MUT-LINC01296 and miR-29c-3p mimic co-transfected HEK-293 T cells was almost unchanged. (c-d) After OVCAR3 and SKOV3 cells were treated with different concentration (50, 100 and 150 nM) of miR-29c-3p inhibitor, we can see that miR-29c-3p inhibitor had notable inhibiting effect on the miR-29c-3p expression when the concentration was 50 (*P < 0.05 vs. control), 100 (**P < 0.01 vs. control) and 150 nM (**P < 0.01 vs. control). (c-d) The expression of miR-29c-3p in SKOV3 and OVCAR3 cells transfected with si-LINC01296 was markedly elevated. **P < 0.01 vs. si-con group

Back to article page